Form 4: Turnstone Biologics Director Acquires Stock Options
SEC Form 4 Filing
William D. Waddill, a director of Turnstone Biologics Corp., acquired stock options for 25,540 shares on April 15, 2024.
Summary
- On April 15, 2024, William D. Waddill, a director of Turnstone Biologics Corp., acquired stock options to purchase 25,540 shares of common stock.
- The exercise price of these options is $2.81 per share.
- The options vest in three annual installments starting on the first anniversary of the grant date, with full vesting occurring on the third anniversary, contingent upon continuous service.
- The options expire on April 14, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of transaction: Director William D. Waddill acquired stock options. |
| 04/14/2034 | Expiration date of the stock options. |
Keywords
stock options, Form 4, director, TSBX, Turnstone Biologics, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.